|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
DISULFIRAM CHRONIC TREATMENT MAY CAUSE REDUCED METABOLISM OF THE DRUG LEADING TO INCREASED PLASMA LEVELS & PROLONGED HALF LIFE OF THE DRUG
|
KETAMINE EFFECT IS PROLONGED WITH SUBSEQUENT DELAY IN RECOVERY DUE TO CONCOMITANT USE
|
SHORTENS THE TIME TO INDUCE ANAESTHESIA WITH MIDAZOLAM
|
SHORTENS THE TIME TO INDUCE ANAESTHESIA WITH MIDAZOLAM
|
SHORTENS THE TIME TO INDUCE ANAESTHESIA WITH MIDAZOLAM
|
SHORTENS THE TIME TO INDUCE ANAESTHESIA WITH MIDAZOLAM
|
SHORTENS THE TIME TO INDUCE ANAESTHESIA WITH MIDAZOLAM
|
SHORTENS THE TIME TO INDUCE ANAESTHESIA WITH MIDAZOLAM
|
SHORTENS THE TIME TO INDUCE ANAESTHESIA WITH MIDAZOLAM
|
SHORTENS THE TIME TO INDUCE ANAESTHESIA WITH MIDAZOLAM
|
SHORTENS THE TIME TO INDUCE ANAESTHESIA WITH MIDAZOLAM
|
SHORTENS THE TIME TO INDUCE ANAESTHESIA WITH MIDAZOLAM
|
SHORTENS THE TIME TO INDUCE ANAESTHESIA WITH MIDAZOLAM
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
PHENYTOIN ENHANCES THE DRUG METABOLISM HENCE DECREASED SERUM LEVELS HAVE BEEN OBSERVED
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES DOSE IS TO BE INCREASED TO ACHIEVE SEDATION ON CONCOMITANT USE. DOSE SHOULD BE REDUCED ONCE THEOPHYLLINE IS WITHDRAWN OTHERWISE TOXICITY APPEARS
|
BENZODIAZEPINES DOSE IS TO BE INCREASED TO ACHIEVE SEDATION ON CONCOMITANT USE. DOSE SHOULD BE REDUCED ONCE THEOPHYLLINE IS WITHDRAWN OTHERWISE TOXICITY APPEARS
|
DIAZEPAM MAY CAUSE RESPIRATORY AND CARDIAC COLLAPSE
|
BENZODIAZEPINES CAN CAUSE RESPIRATORY DEPRESSION BUT DOSE OF BARBITURATE IS DECREASED
|
BENZODIAZEPINES CAN CAUSE RESPIRATORY DEPRESSION BUT DOSE OF BARBITURATE IS DECREASED
|
BENZODIAZEPINES CAN CAUSE RESPIRATORY DEPRESSION BUT DOSE OF BARBITURATE IS DECREASED
|
BENZODIAZEPINES CAN CAUSE RESPIRATORY DEPRESSION BUT DOSE OF BARBITURATE IS DECREASED
|
BENZODIAZEPINES CAN CAUSE RESPIRATORY DEPRESSION BUT DOSE OF BARBITURATE IS DECREASED
|
BENZODIAZEPINES CAN CAUSE RESPIRATORY DEPRESSION BUT DOSE OF BARBITURATE IS DECREASED
|
BENZODIAZEPINES CAN CAUSE RESPIRATORY DEPRESSION BUT DOSE OF BARBITURATE IS DECREASED
|
SAQUINAVIR COMPETES FOR CYP3A ENZYME RESULTING IN IHBITION OF METABOLISM OF OTHER DRUG & CREATE THE POTENTIAL FOR SERIOUS / LIFE THREATENING REACTIONS LIKE CARDIAC ARRHYTHMIAS OR PROLONGED SEDATION
|
CONTRAINDICATED DUE TO POTENTIAL FOR SERIOUS &/OR LIFE THREATENING REACTIONS SUCH AS PROLONGED OR INCREASED SEDATION OR RESPIRATORY DEPRESSION
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF POSTOPERATIVE RESPIRATORY DEPRESSION OR ENHANCE IT
|
NETUPITANT INCREASES SERUM CONC OF THE DRUG BY SIGNIFICANT PERCENTAGE
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
ERYTHROMYCIN DECREASES CLEARANCE OF BENZODIAZEPINES, THUS INCREASE THE PHARMACOLOGIC EFFECT OF THE DRUG SO THEIR DOSE SHOULD BE REDUCED TO 1/3
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|